AMENDMENTS TO THE CLAIMS

1-12 (Cancelled)

13. (Currently Amended) A process for producing a composition for the treatment of a disease, condition or disorder, comprising:

contacting blood or a fraction thereof with a therapeutic substance selected from the group consisting of tetracyclines or tetracycline-like compounds thereby increasing the level of cytokine receptors in the blood or the fraction thereof; and

after the contacting, isolating the blood or the fraction thereof having the increased cytokine receptors.

- 14. (Previously Presented) The process of Claim 13, wherein the contacting is in vivo.
- 15. (Previously Presented) The process of Claim 13, wherein the contacting is in vitro.
- 16. (Previously Presented) The process of Claim 13, wherein the cytokine receptors are increased at least three-fold relative to non-contacted blood or a fraction thereof.
- 17. (Previously Presented) The process of Claim 13, wherein the cytokine receptors are selected from the group consisting of interleukin-1 receptors and tumor necrosis factor receptors.
- 18. (Previously Presented) The process of Claim 13, further comprising processing the isolated blood or fraction thereof by a process selected from the group consisting of: centrifugation, filtration, fractional precipitation, organic solvent precipitation, selective absorption, isoelectric precipitation, and chromatography.
- 19. (Previously Presented) The process of Claim 18, wherein the blood or fraction thereof includes a gamma-globulin fraction, a anti-hemophilia factor fraction, a albumin fraction, serum and plasma.
- 20. (Previously Presented) The process of Claim 13, wherein the disease, condition or disorder includes viral hemorrhagic diseases, sepsis, cachexia, rheumatoid arthritis, acute

10/038,557 2 007841.P001

cardiovascular events, chronic myelogenous leukemia, transplanted bone marrow-induced graftversus-host disease, septic shock, immune complex-induced colitis, cerebrospinal fluid inflammation, autoimmune disorders, multiple sclerosis, systemic inflammatory response syndrome, adult respiratory distress syndrome, acute liver failure, inflammatory bowel disease, or Crohn's disease.

007841.P001 10/038,557